Cart
sales@molnova.com
KRAS G12C inhibitor 16
CAS No. 2349392-79-4
KRAS G12C inhibitor 16( —— )
Catalog No. M32985 CAS No. 2349392-79-4
KRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 604 | In Stock |
|
| 10MG | 809 | In Stock |
|
| 25MG | 1207 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKRAS G12C inhibitor 16
-
NoteResearch use only, not for human use.
-
Brief DescriptionKRAS G12C inhibitor 16 is a potent inhibitor of KRAS G12C.
-
DescriptionKRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 39, has an IC50 of 97 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorKras
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2349392-79-4
-
Formula Weight453.89
-
Molecular FormulaC24H21ClFN3O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCC1=C2C(C=3N4[C@](CN(C(C=C)=O)CC4)(COC3C=N2)[H])=CC(Cl)=C1C5=C(F)C=CC=C5O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Jason Grant Kettle, et al. Tetracyclic compounds as inhibitors of g12c mutant ras protein, for use as anti-cancer agents. WO2019110751A1.
molnova catalog
related products
-
DL-5-Hydroxylysine h...
DL-5-Hydroxylysine is a racemic mixture of D- and L- enantiomers of 5-hydroxylysine which may be used as potential target markers for radical-induced protein oxidation.
-
N-trans-Sinapoyltyra...
N-trans-Sinapoyltyramine exhibited strong and selective cytotoxicity on the HeLa human cancer cell line with IC50 values of 9.77 ± 1.25 Μm.
-
Myosin Kinase Inhibi...
Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer.
